AnaptysBio’s (ANAB) “Neutral” Rating Reaffirmed at HC Wainwright

AnaptysBio (NASDAQ:ANAB)‘s stock had its “neutral” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $19.00 price objective on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 14.05% from the company’s current price.

Other equities analysts have also issued research reports about the stock. UBS Group lifted their price target on shares of AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. BTIG Research lowered shares of AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Monday, December 2nd. JPMorgan Chase & Co. reduced their price target on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a report on Thursday, December 19th. Truist Financial decreased their price objective on AnaptysBio from $30.00 to $20.00 and set a “hold” rating on the stock in a report on Wednesday, December 18th. Finally, Wedbush restated an “outperform” rating and set a $40.00 target price on shares of AnaptysBio in a research report on Monday. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $41.45.

AnaptysBio Price Performance

AnaptysBio stock opened at $16.66 on Tuesday. AnaptysBio has a one year low of $12.51 and a one year high of $41.31. The company’s fifty day moving average price is $17.38 and its two-hundred day moving average price is $27.01. The company has a market capitalization of $506.96 million and a price-to-earnings ratio of -2.74.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The business had revenue of $30.02 million for the quarter, compared to the consensus estimate of $7.92 million. As a group, sell-side analysts anticipate that AnaptysBio will post -6.08 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Ecor1 Capital, Llc bought 6,646 shares of the company’s stock in a transaction dated Thursday, January 2nd. The stock was bought at an average price of $12.95 per share, for a total transaction of $86,065.70. Following the completion of the transaction, the director now directly owns 7,880,094 shares in the company, valued at $102,047,217.30. The trade was a 0.08 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 33.70% of the company’s stock.

Institutional Investors Weigh In On AnaptysBio

Institutional investors and hedge funds have recently modified their holdings of the business. Values First Advisors Inc. bought a new position in shares of AnaptysBio in the 3rd quarter worth $49,000. nVerses Capital LLC boosted its holdings in AnaptysBio by 700.0% during the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after buying an additional 1,400 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of AnaptysBio by 11.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company’s stock worth $85,000 after buying an additional 644 shares during the period. Point72 DIFC Ltd increased its stake in shares of AnaptysBio by 680.5% in the 3rd quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company’s stock valued at $205,000 after acquiring an additional 5,342 shares during the last quarter. Finally, SG Americas Securities LLC raised its position in shares of AnaptysBio by 35.0% in the 4th quarter. SG Americas Securities LLC now owns 16,307 shares of the biotechnology company’s stock valued at $216,000 after acquiring an additional 4,231 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.